Show simple item record

dc.contributor.authorFosse, Vibeke Samuelsen
dc.contributor.authorOldoni, Emanuela
dc.contributor.authorGerardi, Chiara
dc.contributor.authorBanzi, Rita
dc.contributor.authorFratelli, Maddalena
dc.contributor.authorBietrix, Florence
dc.contributor.authorUssi, Anton
dc.contributor.authorAndreu, Antonio L.
dc.contributor.authorMcCormack, Emmet
dc.date.accessioned2022-10-13T14:13:28Z
dc.date.available2022-10-13T14:13:28Z
dc.date.created2022-10-05T14:53:14Z
dc.date.issued2022
dc.identifier.issn2075-4426
dc.identifier.urihttps://hdl.handle.net/11250/3025969
dc.description.abstractThe introduction of personalized medicine, through the increasing multi-omics characterization of disease, brings new challenges to disease modeling. The scope of this review was a broad evaluation of the relevance, validity, and predictive value of the current preclinical methodologies applied in stratified medicine approaches. Two case models were chosen: oncology and brain disorders. We conducted a scoping review, following the Joanna Briggs Institute guidelines, and searched PubMed, EMBASE, and relevant databases for reports describing preclinical models applied in personalized medicine approaches. A total of 1292 and 1516 records were identified from the oncology and brain disorders search, respectively. Quantitative and qualitative synthesis was performed on a final total of 63 oncology and 94 brain disorder studies. The complexity of personalized approaches highlights the need for more sophisticated biological systems to assess the integrated mechanisms of response. Despite the progress in developing innovative and complex preclinical model systems, the currently available methods need to be further developed and validated before their potential in personalized medicine endeavors can be realized. More importantly, we identified underlying gaps in preclinical research relating to the relevance of experimental models, quality assessment practices, reporting, regulation, and a gap between preclinical and clinical research. To achieve a broad implementation of predictive translational models in personalized medicine, these fundamental deficits must be addressed.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleEvaluating Translational Methods for Personalized Medicine—A Scoping Reviewen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 the authorsen_US
dc.source.articlenumber1177en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/jpm12071177
dc.identifier.cristin2058856
dc.source.journalJournal of Personalized Medicineen_US
dc.identifier.citationJournal of Personalized Medicine. 2022, 12 (7), 1177.en_US
dc.source.volume12en_US
dc.source.issue7en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal